NOTCH1 and acute lymphoblastic leukemia: Besides therapeutic strategies directly targeting single components of the NOTCH1 pathway itself (Table 1), the realization that the T-ALL oncogenic process involves multiple NOTCH1 collaborators has revealed new molecular vulnerabilities that offer the opportunity for novel therapeutic developments.